Alexza Pharmaceuticals Inc. (NASDAQ: ALXA) was founded in 2000 and is headquartered in Mountain View, California, USA. It was formerly known as Alexza Molecular Delivery Corporation. It was changed to its current name in July 2005. It is a pharmaceutical company focusing on In the global research, development and commercialization of patented products for acute treatment of the central nervous system.
Alexza Pharmaceuticals (ALXA):
Aleksa Pharmaceuticals’ candidate products are based on its patented technology-Staccato system, which vaporizes into excipient-free drugs, and uses a condensation spray to quickly deliver the drug to the body during inhalation. Alexza Pharmaceuticals’ products and candidate products include:
- ADASUVE (Staccato loxapine) powdered inhalant: used for acute concussion treatment of adult schizophrenia or type I bipolar disorder and other related diseases.
- Engaged in the development of AZ-002 (Staccato alprazolam): for the treatment of patients with acute repetitive seizures, and for the treatment of patients with epilepsy, currently in phase IIa clinical trials,
- AZ-007 (Staccato zaleplon): Used to treat patients with insomnia that is difficult to fall asleep, including waking up in the middle of the night and difficulty falling asleep again.
In addition, Alexa Pharmaceuticals has a cooperation agreement with Grupo Ferrer Internacional SA ( official website ).